Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites. We are experts in the scalable production of DMPK metabolites and generation of polar analogues, and are also a leading provider of unique natural product screening libraries and associated services.
NEWS & EVENTS
20th-22nd September, Basel, Switzerland
Frank will be in Basel for Miptec. Contact us if you are interested in arranging a meeting to learn about our solutions for metabolite production and late-stage functionalisation.
6th – 7th October, Frankfurt, Germany
Come and see us at our booth and listen to an interesting talk by Clive Cornell of Selcia on how Hypha have joined forces with Selcia to produce isotopically labelled natural products and metabolites by microbial biotransformation.
Hypha presented a joint poster with Incyte at the 2016 Drug Discovery Chemistry conference in San Diego. The poster titled “Biocatalytic C-H Activation of the JAK Inhibitor Ruxolitinib” describes how Hypha’s microbial-based biocatalytic technology was applied to produce an array of hydroxylated and further oxidised keto metabolites of first-in-class JAK inhibitor ruxolitinib. Download a copy here